StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID

StemCyte, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared an Expanded Access (EA) program for RegeneCyte®, the company's FDA-licensed hematopoietic progenitor cell ...
KRON4 News

World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical ...

SUZHOU, China, May 25, 2025 /PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic iPSC-derived ...
Medical Dialogues

The future of type 1 diabetes: Can stem cells provide a cure?

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic ...
KXAN

XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury

SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational ...
Becker's ASC

Central Phoenix Surgical Center Adds Progenitor Cell Therapy

Central Phoenix Surgical Center has received approval from various regulatory bodies to add Progenitor Cell Therapy to its list of interventional pain services. Progenitor Cell Proteins are used by ...

StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte(R) (HPC, Cord Blood) to Address Unmet Need in Long COVID

The clearance of this program underscores the vital importance of newborn stem cell preservation. As regenerative medicine continues to evolve, RegeneCyte (R) serves as a primary example of how stored ...